US2016250251A1PendingUtilityA1
Low frequency glatiramer acetate therapy
Est. expiryAug 20, 2029(~3.1 yrs left)· nominal 20-yr term from priority
Inventors:Ety Klinger
A61K 38/16A61K 38/02A61K 9/0019A61K 47/26A61K 38/07A61K 31/785A61P 25/00A61P 3/10A61K 31/19A61K 31/198A61K 9/08A61K 31/195
69
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
A method of alleviating a symptom of relapsing-remitting multiple sclerosis in a human patient suffering from relapsing-remitting multiple sclerosis or a patient who has experienced a first clinical episode and is determined to be at high risk of developing clinically definite multiple sclerosis comprising administering to the human patient three subcutaneous injections of a therapeutically effective dose of glatiramer acetate over a period of seven days with at least one day between every subcutaneous injection so as to thereby alleviate the symptom of the patient.
Claims
exact text as granted — not AI-modified1 . A method of alleviating a symptom of relapsing-remitting multiple sclerosis in a human patient suffering from relapsing-remitting multiple sclerosis or a patient who has experienced a first clinical episode and is determined to be at high risk of developing clinically definite multiple sclerosis comprising administering to the human patient three subcutaneous injections of a therapeutically effective dose of glatiramer acetate over a period of seven days with at least one day between every subcutaneous injection so as to thereby alleviate the symptom of the patient.
2 .- 21 . (canceled)
22 . A method of increasing the tolerability of GA treatment in a human patient suffering from relapsing-remitting multiple sclerosis or a patient who has experienced a first clinical episode and is determined to be at high risk of developing clinically definite multiple sclerosis which comprises reducing the frequency of subcutaneous injections of a pharmaceutical composition comprising a therapeutically effective dose of glatiramer acetate to three times over a period of seven days with at least one day between every injection.
23 .- 32 . (canceled)Join the waitlist — get patent alerts
Track US2016250251A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.